Signals
3AL amyloidosis therapy reshapes around daratumumab and emerging amyloid-targeted programs
Daratumumab plus bortezomib first-line, isatuximab follow-on programs, and emerging anti-amyloid antibody therapy are restructuring AL amyloidosis management.
MASH therapy class establishes after resmetirom approval
Resmetirom commercial uptake plus follow-on FGF21 analogues, GLP-1 plus glucagon, and PPAR-pan agonists are establishing a real metabolic-dysfunction-associated steatohepatitis prescribing class.
ATTR amyloidosis silencer therapy uptake is transforming a previously underdiagnosed condition
Transthyretin amyloid cardiomyopathy (ATTR-CM) was historically underdiagnosed and undertreated. Approved silencer therapies (siRNA, ASO) and TTR stabilisers have moved the field rapidly, and the diagnostic-pathway access remains the rate-limit on commercial uptake.
Snapshots
3Cardiac amyloidosis therapy reference (2026)
Reference snapshot of cardiac amyloidosis therapy across AL and ATTR types.
Type 1 diabetes therapy reference (2026)
Reference snapshot of T1D therapy across insulin delivery, disease modification, and beta-cell replacement.
ATTR cardiomyopathy treatment landscape, 2026 mid-year reference
Reference layout of the ATTR cardiomyopathy treatment landscape as of mid-2026: TTR stabilisers, TTR silencers, the diagnostic-pathway infrastructure, and the live commercial questions including diagnostic-pathway expansion and combination therapy.
Explained
4What is AL amyloidosis?
Plain-language primer on AL amyloidosis, why early diagnosis matters so much, and how modern therapy works.
PCSK9 inhibitors and modern lipid therapy explained
Plain-language primer on PCSK9 and the modern range of lipid-lowering options.
What is heart failure?
Plain-language primer on heart failure, why the modern therapy is built around four foundational classes, and what is changing.
What is type 1 diabetes?
Plain-language primer on type 1 diabetes, what is changing, and how modern therapy works.